Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience.
Aged
Aged, 80 and over
Anti-Bacterial Agents
/ therapeutic use
Cephalosporins
/ therapeutic use
Humans
Middle Aged
Pseudomonas Infections
/ diagnosis
Pseudomonas aeruginosa
/ isolation & purification
Skin Diseases, Bacterial
/ diagnosis
Soft Tissue Infections
/ diagnosis
Tazobactam
/ therapeutic use
Treatment Outcome
Antibiotic resistance
Ceftolozane/tazobactam
Kidney disease
Pseudomonas aeruginosa
Skin and soft tissue infections
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
24
09
2019
accepted:
13
01
2020
pubmed:
26
1
2020
medline:
3
4
2020
entrez:
26
1
2020
Statut:
ppublish
Résumé
Pseudomonas aeruginosa (PA) is a known cause of skin and soft tissue infections (SSTIs). Therapeutic options against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of PA are limited, especially in patients with impaired renal function. Ceftolozane/tazobactam (C/T) is a novel beta-lactam/beta-lactamase inhibitor with powerful anti-PA activity. Thanks to its characteristics, it appears to be the best available anti-pseudomonal drug in many clinical scenarios. A case series of four adult patients followed between January 2018 and May 2019 is reported. All subjects presented complicated SSTIs by MDR- or XDR-PA and were affected by chronic kidney disease. C/T was used as a monotherapy in three cases and in combination regimen in the remaining case. In two cases, C/T was the first-line option, in the remaining ones was the salvage treatment. All patients were successfully treated without worsening of renal function and without any other adverse events. C/T may represent a useful option against MDR- and XDR-PA strains responsible of complicated SSTIs in patients affected by impaired renal function.
Identifiants
pubmed: 31981091
doi: 10.1007/s15010-020-01390-y
pii: 10.1007/s15010-020-01390-y
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cephalosporins
0
ceftolozane, tazobactam drug combination
0
Tazobactam
SE10G96M8W
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
303-307Références
Ruiz-Garbajosa P, Canton R. Epidemiology of antibiotic resistance in Pseudomonas aeruginosa Implications for empiric and definitive therapy. Rev Esp Quimioter. 2017;30:8–12.
pubmed: 28882007
Rojas A, Palacios-Baena ZR, Lopez-Cortes LE, Rodriguez-Bano J. Rates, predictors and mortality of community-onset bloodstream infections due to Pseudomonas aeruginosa: systematic review and meta-analysis. Clin Microbiol Infect. 2019;25:964–70.
doi: 10.1016/j.cmi.2019.04.005
Palavutitotai N, Jitmuang A, Tongsai S, Kiratisin P, Angkasekwinai N. Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections. PLoS ONE. 2018;13:e0193431.
doi: 10.1371/journal.pone.0193431
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318–27.
doi: 10.1016/S1473-3099(17)30753-3
Bassetti M, Vena A, Croxatto A, Righi E, Guery B. How to manage Pseudomonas aeruginosa infections. Drugs Context. 2018;7:212527.
doi: 10.7573/dic.212527
Leong HN, Kurup A, Tan MY, Kwa ALH, Liau KH, Wilcox MH. Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics. Infect Drug Resist. 2018;11:1959–74.
doi: 10.2147/IDR.S172366
Maraolo AE, Cascella M, Corcione S, Cuomo A, Nappa S, Borgia G, et al. Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art. Exp Rev Anti-infect Ther. 2017;15:861–71.
doi: 10.1080/14787210.2017.1367666
Gentile I, Maraolo AE, Borgia G. What is the role of the new beta-lactam/beta-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam? Exp Rev Anti-infect Ther. 2016;14:875–8.
doi: 10.1080/14787210.2016.1233060
Wooley M, Miller B, Krishna G, Hershberger E, Chandorkar G. Impact of renal function on the pharmacokinetics and safety of ceftolozane–tazobactam. Antimicrob Agents Chemother. 2014;58:2249–55.
doi: 10.1128/AAC.02151-13
Magiorakos AP, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81.
doi: 10.1111/j.1469-0691.2011.03570.x
Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother. 2010;65:iii35–44.
doi: 10.1093/jac/dkq302
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO. clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2012;2013:1–150.
Mensa J, Barberan J, Soriano A, Llinares P, Marco F, Canton R, et al. Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: guidelines by the Spanish Society of Chemotherapy. Rev Esp Quimioter. 2018;31:78–100.
pubmed: 29480677
pmcid: 6159363
Gentile I, Buonomo AR, Maraolo AE, Scotto R, De Zottis F, Di Renzo G, et al. Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy. J Antimicrob Chemother. 2017;72:2678–9.
doi: 10.1093/jac/dkx172
Frattari A, Savini V, Polilli E, Cibelli D, Talamazzi S, Bosco D, et al. Ceftolozane–tazobactam and Fosfomycin for rescue treatment of otogenous meningitis caused by XDR Pseudomonas aeruginosa: case report and review of the literature. IDCases. 2018;14:e00451.
doi: 10.1016/j.idcr.2018.e00451
Martin-Cazana M, Grau S, Epalza C, Branas P, Flores M, Olmedilla M, et al. Successful ceftolozane–tazobactam rescue therapy in a child with endocarditis caused by multidrug-resistant Pseudomonas aeruginosa. J Paediatr Child Health. 2019;55:985–7.
doi: 10.1111/jpc.14388
Bassetti M, Castaldo N, Cattelan A, Mussini C, Righi E, Tascini C, et al. Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. Int J Antimicrob Agents. 2019;53:408–15.
doi: 10.1016/j.ijantimicag.2018.11.001
Gallagher JC, Satlin MJ, Elabor A, Saraiya N, McCreary EK, Molnar E, et al. Ceftolozane–tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study. Open Forum Infect Dis. 2018;5:ofy280.
doi: 10.1093/ofid/ofy280
Maraolo AE, Mazzitelli M, Trecarichi EM, Buonomo AR, Torti C, Gentile I. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: a systematic review about its efficacy and safety for off-label indications. Int J Antimicrob Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.105891 (Epub ahead of print).
doi: 10.1016/j.ijantimicag.2020.105891
pubmed: 31923569
European Medicines Agency (EMA). Zerbaxa. Annex I. Summary of product characteristics. https://www.ema.europa.eu/en/medicines/human/EPAR/zerbaxa#product-information-section . Accessed 8 Jun 2019
Kullar R, Wagenlehner FM, Popejoy MW, Long J, Yu B, Goldstein EJ. Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam. J Antimicrob Chemother. 2017;72:900–5.
pubmed: 27999024
Crass RL, Rodvold KA, Mueller BA, Pai MP. Renal dosing of antibiotics: are we jumping the gun? Clin Infect Dis. 2019;68:1596–602.
doi: 10.1093/cid/ciy790